GB202002581D0 - Novel antibodies - Google Patents

Novel antibodies

Info

Publication number
GB202002581D0
GB202002581D0 GBGB2002581.3A GB202002581A GB202002581D0 GB 202002581 D0 GB202002581 D0 GB 202002581D0 GB 202002581 A GB202002581 A GB 202002581A GB 202002581 D0 GB202002581 D0 GB 202002581D0
Authority
GB
United Kingdom
Prior art keywords
novel antibodies
antibodies
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2002581.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GammaDelta Therapeutics Ltd
Original Assignee
GammaDelta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GammaDelta Therapeutics Ltd filed Critical GammaDelta Therapeutics Ltd
Priority to GBGB2002581.3A priority Critical patent/GB202002581D0/en
Publication of GB202002581D0 publication Critical patent/GB202002581D0/en
Priority to JP2022550813A priority patent/JP2023514437A/ja
Priority to CA3172340A priority patent/CA3172340A1/en
Priority to CN202180028136.1A priority patent/CN115697401A/zh
Priority to PE2022001812A priority patent/PE20230438A1/es
Priority to CN202180030584.5A priority patent/CN115461369A/zh
Priority to AU2021225390A priority patent/AU2021225390A1/en
Priority to JP2022550778A priority patent/JP2023516925A/ja
Priority to IL295696A priority patent/IL295696A/en
Priority to MX2022010239A priority patent/MX2022010239A/es
Priority to EP21709757.5A priority patent/EP4110813A1/en
Priority to US17/904,890 priority patent/US20230159638A1/en
Priority to BR112022016671A priority patent/BR112022016671A2/pt
Priority to PCT/GB2021/050460 priority patent/WO2021171003A1/en
Priority to US17/801,786 priority patent/US20230090901A1/en
Priority to MX2022010383A priority patent/MX2022010383A/es
Priority to BR112022016894A priority patent/BR112022016894A2/pt
Priority to AU2021228266A priority patent/AU2021228266A1/en
Priority to KR1020227029501A priority patent/KR20220164473A/ko
Priority to PCT/GB2021/050459 priority patent/WO2021171002A1/en
Priority to CA3168973A priority patent/CA3168973A1/en
Priority to IL295852A priority patent/IL295852A/en
Priority to EP25177102.8A priority patent/EP4591882A3/en
Priority to EP21709758.3A priority patent/EP4110387B1/en
Priority to KR1020227033455A priority patent/KR20220145894A/ko
Priority to CL2022002296A priority patent/CL2022002296A1/es
Priority to ZA2022/09699A priority patent/ZA202209699B/en
Priority to CONC2022/0013542A priority patent/CO2022013542A2/es
Priority to CONC2022/0013633A priority patent/CO2022013633A2/es
Priority to ECSENADI202274030A priority patent/ECSP22074030A/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB2002581.3A 2020-02-24 2020-02-24 Novel antibodies Ceased GB202002581D0 (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
GBGB2002581.3A GB202002581D0 (en) 2020-02-24 2020-02-24 Novel antibodies
KR1020227033455A KR20220145894A (ko) 2020-02-24 2021-02-24 신규 항체
US17/801,786 US20230090901A1 (en) 2020-02-24 2021-02-24 Novel antibodies
MX2022010383A MX2022010383A (es) 2020-02-24 2021-02-24 Anticuerpos novedosos.
CN202180028136.1A CN115697401A (zh) 2020-02-24 2021-02-24 离体γδT细胞群体
PE2022001812A PE20230438A1 (es) 2020-02-24 2021-02-24 Anticuerpos novedosos
CN202180030584.5A CN115461369A (zh) 2020-02-24 2021-02-24 新型抗体
AU2021225390A AU2021225390A1 (en) 2020-02-24 2021-02-24 Ex vivo gamma delta T cell populations
JP2022550778A JP2023516925A (ja) 2020-02-24 2021-02-24 新規の抗体
IL295696A IL295696A (en) 2020-02-24 2021-02-24 In vitro gamma delta t cell populations
MX2022010239A MX2022010239A (es) 2020-02-24 2021-02-24 Poblaciones de linfocitos t gamma delta ex vivo.
EP21709757.5A EP4110813A1 (en) 2020-02-24 2021-02-24 Novel antibodies
US17/904,890 US20230159638A1 (en) 2020-02-24 2021-02-24 Ex vivo gamma delta t cell populations
BR112022016671A BR112022016671A2 (pt) 2020-02-24 2021-02-24 Método ex vivo de modulação de células t gama variável 4, população de células t vy4, composição, composição farmacêutica, e, método de tratamento de um câncer, uma doença infecciosa ou uma doença inflamatória em um sujeito em necessidade
PCT/GB2021/050460 WO2021171003A1 (en) 2020-02-24 2021-02-24 Ex vivo gamma delta t cell populations
JP2022550813A JP2023514437A (ja) 2020-02-24 2021-02-24 Ｅｘ ｖｉｖｏガンマデルタｔ細胞集団
BR112022016894A BR112022016894A2 (pt) 2020-02-24 2021-02-24 Anticorpos novos
IL295852A IL295852A (en) 2020-02-24 2021-02-24 New antibodies
EP21709758.3A EP4110387B1 (en) 2020-02-24 2021-02-24 Ex vivo gamma delta t cell populations
KR1020227029501A KR20220164473A (ko) 2020-02-24 2021-02-24 생체외 감마 델타 t 세포 집단
PCT/GB2021/050459 WO2021171002A1 (en) 2020-02-24 2021-02-24 Novel antibodies
CA3168973A CA3168973A1 (en) 2020-02-24 2021-02-24 Antibodies against t cell receptor of gamma delta (y.delta.) t cells
CA3172340A CA3172340A1 (en) 2020-02-24 2021-02-24 Ex vivo gamma delta t cell populations
EP25177102.8A EP4591882A3 (en) 2020-02-24 2021-02-24 Ex vivo gamma delta t cell populations
AU2021228266A AU2021228266A1 (en) 2020-02-24 2021-02-24 Novel antibodies
CL2022002296A CL2022002296A1 (es) 2020-02-24 2022-08-23 Anticuerpos novedosos
ZA2022/09699A ZA202209699B (en) 2020-02-24 2022-08-30 Novel antibodies
CONC2022/0013542A CO2022013542A2 (es) 2020-02-24 2022-09-21 Poblaciones de linfocitos t gamma delta ex vivo
CONC2022/0013633A CO2022013633A2 (es) 2020-02-24 2022-09-22 Anticuerpos novedosos
ECSENADI202274030A ECSP22074030A (es) 2020-02-24 2022-09-22 Anticuerpos novedosos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2002581.3A GB202002581D0 (en) 2020-02-24 2020-02-24 Novel antibodies

Publications (1)

Publication Number Publication Date
GB202002581D0 true GB202002581D0 (en) 2020-04-08

Family

ID=70108379

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2002581.3A Ceased GB202002581D0 (en) 2020-02-24 2020-02-24 Novel antibodies

Country Status (17)

Country Link
US (2) US20230159638A1 (https=)
EP (3) EP4591882A3 (https=)
JP (2) JP2023516925A (https=)
KR (2) KR20220145894A (https=)
CN (2) CN115697401A (https=)
AU (2) AU2021228266A1 (https=)
BR (2) BR112022016894A2 (https=)
CA (2) CA3168973A1 (https=)
CL (1) CL2022002296A1 (https=)
CO (2) CO2022013542A2 (https=)
EC (1) ECSP22074030A (https=)
GB (1) GB202002581D0 (https=)
IL (2) IL295852A (https=)
MX (2) MX2022010383A (https=)
PE (1) PE20230438A1 (https=)
WO (2) WO2021171002A1 (https=)
ZA (1) ZA202209699B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
AU2022222299A1 (en) 2021-02-17 2023-09-07 F-Star Therapeutics Limited Multispecific anti-tcr delta variable 1 antibodies
CN119080924B (zh) * 2024-07-04 2025-02-25 上海交通大学医学院附属第九人民医院 一种单克隆免疫球蛋白及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081518A2 (en) * 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
AU2016274633B2 (en) * 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
EP3454870A4 (en) * 2016-05-12 2020-03-04 Adicet Bio Inc. METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
CA3145523A1 (en) * 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Therapeutic uses of anti-tcr delta variable 1 antibodies

Also Published As

Publication number Publication date
CO2022013542A2 (es) 2022-10-11
BR112022016671A2 (pt) 2022-11-16
CO2022013633A2 (es) 2023-02-16
JP2023514437A (ja) 2023-04-05
CN115697401A (zh) 2023-02-03
AU2021228266A1 (en) 2022-10-13
EP4591882A2 (en) 2025-07-30
EP4591882A3 (en) 2025-10-15
ECSP22074030A (es) 2022-10-31
CA3172340A1 (en) 2021-09-02
MX2022010239A (es) 2022-11-14
PE20230438A1 (es) 2023-03-08
MX2022010383A (es) 2022-09-05
IL295852A (en) 2022-10-01
WO2021171002A1 (en) 2021-09-02
EP4110387A1 (en) 2023-01-04
CN115461369A (zh) 2022-12-09
AU2021225390A1 (en) 2022-09-22
BR112022016894A2 (pt) 2023-04-04
WO2021171003A1 (en) 2021-09-02
CA3168973A1 (en) 2021-09-02
EP4110813A1 (en) 2023-01-04
CL2022002296A1 (es) 2023-03-31
US20230090901A1 (en) 2023-03-23
EP4110387B1 (en) 2025-05-21
KR20220145894A (ko) 2022-10-31
JP2023516925A (ja) 2023-04-21
US20230159638A1 (en) 2023-05-25
IL295696A (en) 2022-10-01
ZA202209699B (en) 2024-12-18
KR20220164473A (ko) 2022-12-13

Similar Documents

Publication Publication Date Title
SG11202108141VA (en) Novel cd40-binding antibodies
IL308741A (en) Anti-SIRP-alpha antibodies
PT4214240T (pt) Anticorpos anti-ccr8
GB202105110D0 (en) Anti-CD73 antibodies
EP4377358A4 (en) NEW ANTI-SIRPA ANTIBODIES
GB202111905D0 (en) Antibodies
ZA202209699B (en) Novel antibodies
GB202014851D0 (en) SARS-COV-2 antibodies
IL300142A (en) Anti-IL13Ralpha2 antibodies
GB2627309B (en) Antibodies
IL308782A (en) Antibodies
IL308100A (en) Antibodies
GB202204159D0 (en) Antibodies
GB202102227D0 (en) Antibodies
GB202008022D0 (en) Antibodies
IL312391A (en) New anti-IL-36R antibodies
GB202010760D0 (en) Novel antibodies
GB202208773D0 (en) Anti-SARS2-S antibodies
IL307175A (en) IL-38 specific antibodies
GB202116709D0 (en) Antibodies
GB202115824D0 (en) Antibodies
GB202112297D0 (en) Antibodies
GB202107517D0 (en) Antibodies
GB202104128D0 (en) Antibodies
GB202103388D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)